What to expect from targeted radioisotope therapy for neuroendocrine tumours

The team first confirms that the tumour cells carry the marker the treatment is designed to recognise. Blood tests, kidney checks, medicines and imaging help determine whether therapy is appropriate. Fluids and protective medicines may be given before, during or after the infusion.

The radioisotope is delivered through a vein and travels to cells with the matching target. Because radiation can leave through urine and other fluids, you may spend time in a designated room and receive instructions about distance, hygiene and contact at home. Nausea, tiredness, abdominal discomfort and temporary blood-count changes are possible.

Share your complete medicine list and report kidney problems, pregnancy concerns, allergies or recent infection. Arrange transport and practical help if the unit advises it. Drink and use the toilet as instructed, take prescribed anti-sickness medicine, and attend scheduled blood tests and scans. Keep the discharge guidance accessible for anyone helping you.

Contact your treatment team for fever, persistent vomiting, inability to keep fluids down, markedly reduced urine, unusual bleeding or bruising, or increasing pain. Get urgent help for collapse, severe breathing difficulty, a serious allergic reaction or uncontrolled bleeding. Ask before taking a new medicine, including non-prescription products.

Ask how the target was confirmed, what medicines protect the kidneys or other organs, how long radiation precautions last, which symptoms need urgent review, and how treatment response will be assessed. Clarify plans for work, travel, family contact and follow-up with your usual specialist.